HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

29

Enrollment

INDUSTRY

Sponsor class

Stopped slow accrual \& early closure

Conditions

Metastatic Melanoma

Interventions

DRUG: High Dose Interleukin-2
DRUG: Ipilimumab

Sponsor

Clinigen, Inc.

Collaborators

[object Object]
[object Object]